17.06.2022 | WHAT IS THIS IMAGE?
What is this image? 2022 image 1 result: radiologic improvement of transthyretin cardiac amyloidosis after treatment with tafamidis
verfasst von:
Raktham Mekritthikrai, MD, Javier Gomez-Valencia, MD, MS, FASNC, Saurabh Malhotra, MD, MPH, FASNC
Erschienen in:
Journal of Nuclear Cardiology
|
Ausgabe 4/2022
Einloggen, um Zugang zu erhalten
Excerpt
Transthyretin cardiac amyloidosis (ATTR-CA) is an infiltrative cardiomyopathy caused by the deposition of amyloid protein leading to heart failure. Presence of ATTR-CA is often suggested by echocardiography and cardiac magnetic resonance (CMR), and confirmed by technetium-99m pyrophosphate (PYP) scintigraphy or endomyocardial biopsy. Tafamidis is a transthyretin stabilizer that has been shown to improve cardiovascular outcomes among patients with ATTR-CA.
1 Improvement in cardiac function and imaging evidence of change in amyloid burden after tafamidis has not been documented. …